The global pharmaceutical industry experienced a 24% decline in the number of future of work-related patent applications in Q2 2024 compared with the previous quarter. The total number of future of work-related grants rose by 14% in Q2 2024, according to GlobalData’s Patent Analytics. GlobalData’s databook Pharma: Patents Trends Q2 2024 offers comprehensive insights into patenting trends, major players’ strategies, and geographical focus in the sector over the last three years. Buy the databook here.
Notably, the number of future of work-related patent applications in the pharmaceutical industry was 879 in Q2 2024, versus 1,159 in the prior quarter.
The top five companies accounted for 5% of patenting activity
Analysis of patenting activity by companies shows that Danaher filed the most future of work patents within the pharmaceutical industry in Q2 2024. The company filed 17 future of work-related patents in the quarter, compared with 23 in the previous quarter. It was followed by Sartorius with 6 future of work patent filings, Regeneron Pharmaceuticals (6 filings), and Becton Dickinson and Co (6 filings) in Q2 2024.
Patenting activity was driven by China with a 45% share of total patent filings
The largest share of future of work related patent filings in the pharmaceutical industry in Q2 2024 was in China with 45%, followed by the US (16%) and Japan (5%). The share represented by China was 4% higher than the 41% share it accounted for in Q1 2024.
For further understanding of GlobalData's Pharma: Patents Trends Q2 2024, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.